Dopamine inhibits the effector functions of activated NK cells via the upregulation of the D5 receptor

Journal of Immunology

Volumn 193, Issue 6, 2014, Pages 2792-2800

  Mikulak, Joanna ^a   Bozzo, Luisa ^a   Roberto, Alessandra ^a   Pontarini, Elena ^a   Tentorio, Paolo ^a   Hudspeth, Kelly ^a   Lugli, Enrico ^a   Mavilio, Domenico ^a,b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA 29A; PROTEIN P50; RECOMBINANT INTERLEUKIN 2; TRANSCRIPTION FACTOR REL; INTERLEUKIN 2; MICRORNA; MIRN29 MICRORNA, MOUSE; PROTEIN BINDING; RECOMBINANT PROTEIN;

ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; HUMAN; HUMAN CELL; IMMUNOREGULATION; INHIBITION KINETICS; LYMPHOCYTE PROLIFERATION; NATURAL KILLER CELL; PHARMACOLOGICAL BLOCKING; PROMOTER REGION; RECEPTOR BINDING; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL PROLIFERATION; CYTOTOXICITY; GENETICS; HEK293 CELL LINE; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE ACTIVATION; TUMOR CELL LINE; UPREGULATION;

CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; DOPAMINE; HEK293 CELLS; HUMANS; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICRORNAS; NF-KAPPA B P50 SUBUNIT; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-REL; RECEPTORS, DOPAMINE D5; RECOMBINANT PROTEINS; UP-REGULATION;

EID: 84908376925     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401114     Document Type: Article

References (72)

1. Qiu, Y., Y. Peng, and J. Wang. 1996. Immunoregulatory role of neurotransmitters. Adv. Neuroimmunol. 6:223-231.
2. Weigent, D. A., and J. E. Blalock. 1987. Interactions between the neuroendocrine and immune systems: common hormones and receptors. Immunol. Rev. 100:79-108.
3. Bencsics, A., H. Sershen, M. Baranyi, A. Hashim, A. Lajtha, and E. S. Vizi. 1997. Dopamine, as well as norepinephrine, is a link between noradrenergic nerve terminals and splenocytes. Brain Res. 761:236-243.
4. Haskó, G., and C. Szabó. 1998. Regulation of cytokine and chemokine production by transmitters and co-transmitters of the autonomic nervous system. Biochem. Pharmacol. 56:1079-1087.
5. Mignini, F., V. Streccioni, and F. Amenta. 2003. Autonomic innervation of immune organs and neuroimmune modulation. Auton. Autacoid Pharmacol. 23:1-25.
6. Ferrari, M., M. Cosentino, F. Marino, R. Bombelli, E. Rasini, S. Lecchini, and G. Frigo. 2004. Dopaminergic D1-like receptor-dependent inhibition of tyrosine hydroxylase mRNA expression and catecholamine production in human lymphocytes. Biochem. Pharmacol. 67:865-873.
7. Kirillova, G. P., R. J. Hrutkay, M. R. Shurin, G. V. Shurin, I. L. Tourkova, and M. M. Vanyukov. 2008. Dopamine receptors in human lymphocytes: radioligand binding and quantitative RT-PCR assays. J. Neurosci. Methods 174:272-280.
8. McKenna, F., P. J. McLaughlin, B. J. Lewis, G. C. Sibbring, J. A. Cummerson, D. Bowen-Jones, and R. J. Moots. 2002. Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. J. Neuroimmunol. 132:34-40.
9. Nakano, K., T. Higashi, K. Hashimoto, R. Takagi, Y. Tanaka, and S. Matsushita. 2008. Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis. Biochem. Biophys. Res. Commun. 373:286-291.
10. Nakano, K., T. Higashi, R. Takagi, K. Hashimoto, Y. Tanaka, and S. Matsushita. 2009. Dopamine released by dendritic cells polarizes Th2 differentiation. Int. Immunol. 21:645-654.
11. Besser, M. J., Y. Ganor, and M. Levite. 2005. Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNFalpha or both. J. Neuroimmunol. 169:161-171.
12. Ghosh, M. C., A. C. Mondal, S. Basu, S. Banerjee, J. Majumder, D. Bhattacharya, and P. S. Dasgupta. 2003. Dopamine inhibits cytokine release and expression of tyrosine kinases, Lck and Fyn in activated T cells. Int. Immunopharmacol. 3:1019-1026.
13. Levite, M., Y. Chowers, Y. Ganor, M. Besser, R. Hershkovits, and L. Cahalon. 2001. Dopamine interacts directly with its D3 and D2 receptors on normal human T cells, and activates beta1 integrin function. Eur. J. Immunol. 31:3504-3512.
14. Sarkar, C., S. Das, D. Chakroborty, U. R. Chowdhury, B. Basu, P. S. Dasgupta, and S. Basu. 2006. Cutting Edge: Stimulation of dopamine D4 receptors induce T cell quiescence by up-regulating Kruppel-like factor-2 expression through inhibition of ERK1/ERK2 phosphorylation. J. Immunol. 177:7525-7529.
15. Watanabe, Y., T. Nakayama, D. Nagakubo, K. Hieshima, Z. Jin, F. Katou, K. Hashimoto, and O. Yoshie. 2006. Dopamine selectively induces migration and homing of naive CD8+ T cells via dopamine receptor D3. J. Immunol. 176:848-856.
16. Pacheco, R., C. E. Prado, M. J. Barrientos, and S. Bernales. 2009. Role of dopamine in the physiology of T-cells and dendritic cells. J. Neuroimmunol. 216:8-19.
17. Sarkar, C., B. Basu, D. Chakroborty, P. S. Dasgupta, and S. Basu. 2010. The immunoregulatory role of dopamine: an update. Brain Behav. Immun. 24:525-528.
18. Sibley, D. R., F. J. Monsma, Jr., and Y. Shen. 1993. Molecular neurobiology of dopaminergic receptors. Int. Rev. Neurobiol. 35:391-415.
19. Lachowicz, J. E., and D. R. Sibley. 1997. Molecular characteristics of mammalian dopamine receptors. Pharmacol. Toxicol. 81:105-113.
20. Missale, C., S. R. Nash, S. W. Robinson, M. Jaber, and M. G. Caron. 1998. Dopamine receptors: from structure to function. Physiol. Rev. 78:189-225.
21. Neve, K. A., J. K. Seamans, and H. Trantham-Davidson. 2004. Dopamine receptor signaling. J. Recept. Signal Transduct. Res. 24:165-205.
22. Cosentino, M., A. M. Fietta, M. Ferrari, E. Rasini, R. Bombelli, E. Carcano, F. Saporiti, F. Meloni, F. Marino, and S. Lecchini. 2007. Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop. Blood 109:632-642.
23. Saha, B., A. C. Mondal, J. Majumder, S. Basu, and P. S. Dasgupta. 2001. Physiological concentrations of dopamine inhibit the proliferation and cytotoxicity of human CD4+ and CD8+ T cells in vitro: a receptor-mediated mechanism. Neuroimmunomodulation 9:23-33.
24. Chang, J. Y., and L. Z. Liu. 2000. Catecholamines inhibit microglial nitric oxide production. Brain Res. Bull. 52:525-530.
25. Vivier, E., D. H. Raulet, A. Moretta, M. A. Caligiuri, L. Zitvogel, L. L. Lanier, W. M. Yokoyama, and S. Ugolini. 2011. Innate or adaptive immunity? The example of natural killer cells. Science 331:44-49.
26. Brunetta, E., K. L. Hudspeth, and D. Mavilio. 2010. Pathologic natural killer cell subset redistribution in HIV-1 infection: new insights in pathophysiology and clinical outcomes. J. Leukoc. Biol. 88:1119-1130.
27. Cooper, M. A., T. A. Fehniger, and M. A. Caligiuri. 2001. The biology of human natural killer-cell subsets. Trends Immunol. 22:633-640.
28. Teunis, M. A., C. J. Heijnen, A. R. Cools, and A. Kavelaars. 2004. Reduced splenic natural killer cell activity in rats with a hyperreactive dopaminergic system. Psychoneuroendocrinology 29:1058-1064.
29. Kavelaars, A., P. M. Cobelens, M. A. Teunis, and C. J. Heijnen. 2005. Changes in innate and acquired immune responses in mice with targeted deletion of the dopamine transporter gene. J. Neuroimmunol. 161:162-168.
30. Zhao, W., Y. Huang, Z. Liu, B. B. Cao, Y. P. Peng, and Y. H. Qiu. 2013. Dopamine receptors modulate cytotoxicity of natural killer cells via cAMP-PKACREB signaling pathway. PLoS ONE 8:e65860.
31. Ma, F., S. Xu, X. Liu, Q. Zhang, X. Xu, M. Liu, M. Hua, N. Li, H. Yao, and X. Cao. 2011. The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-g. Nat. Immunol. 12:861-869.
32. Fogli, M., D. Mavilio, E. Brunetta, S. Varchetta, K. Ata, G. Roby, C. Kovacs, D. Follmann, D. Pende, J. Ward, et al. 2008. Lysis of endogenously infected CD4+ T cell blasts by rIL-2 activated autologous natural killer cells from HIV-infected viremic individuals. PLoS Pathog. 4:e1000101.
33. Gupta, N., J. Arthos, P. Khazanie, T. D. Steenbeke, N. M. Censoplano, E. A. Chung, C. C. Cruz, M. A. Chaikin, M. Daucher, S. Kottilil, et al. 2005. Targeted lysis of HIV-infected cells by natural killer cells armed and triggered by a recombinant immunoglobulin fusion protein: implications for immunotherapy. Virology 332:491-497.
34. Brunetta, E., M. Fogli, S. Varchetta, L. Bozzo, K. L. Hudspeth, E. Marcenaro, A. Moretta, and D. Mavilio. 2009. The decreased expression of Siglec-7 represents an early marker of dysfunctional natural killer-cell subsets associated with high levels of HIV-1 viremia. Blood 114:3822-3830.
35. Correia, D. V., M. Fogli, K. Hudspeth, M. G. da Silva, D. Mavilio, and B. Silva-Santos. 2011. Differentiation of human peripheral blood Vd1+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells. Blood 118:992-1001.
36. Brunetta, E., M. Fogli, S. Varchetta, L. Bozzo, K. L. Hudspeth, E. Marcenaro, A. Moretta, and D. Mavilio. 2010. Chronic HIV-1 viremia reverses NKG2A/NKG2C ratio on natural killer cells in patients with human cytomegalovirus coinfection. AIDS 24:27-34.
37. Saha, B., A. C. Mondal, S. Basu, and P. S. Dasgupta. 2001. Circulating dopamine level, in lung carcinoma patients, inhibits proliferation and cytotoxicity of CD4+ and CD8+ T cells by D1 dopamine receptors: an in vitro analysis. Int. Immunopharmacol. 1:1363-1374.
38. Kipnis, J., M. Cardon, H. Avidan, G. M. Lewitus, S. Mordechay, A. Rolls, Y. Shani, and M. Schwartz. 2004. Dopamine, through the extracellular signalregulated kinase pathway, downregulates CD4+CD25+ regulatory T-cell activity: implications for neurodegeneration. J. Neurosci. 24:6133-6143.
39. Mavilio, D., G. Lombardo, A. Kinter, M. Fogli, A. La Sala, S. Ortolano, A. Farschi, D. Follmann, R. Gregg, C. Kovacs, et al. 2006. Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. J. Exp. Med. 203:2339-2350.
40. Leonard, W. J., and R. Spolski. 2005. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat. Rev. Immunol. 5:688-698.
41. Malarkannan, S., J. Regunathan, H. Chu, S. Kutlesa, Y. Chen, H. Zeng, R. Wen, and D. Wang. 2007. Bcl10 plays a divergent role in NK cell-mediated cytotoxicity and cytokine generation. J. Immunol. 179:3752-3762.
42. Gross, O., C. Grupp, C. Steinberg, S. Zimmermann, D. Strasser, N. Hannesschläger, W. Reindl, H. Jonsson, H. Huo, D. R. Littman, et al. 2008. Multiple ITAM-coupled NK-cell receptors engage the Bcl10/Malt1 complex via Carma1 for NF-kappaB and MAPK activation to selectively control cytokine production. Blood 112:2421-2428.
43. Mott, J. L., S. Kurita, S. C. Cazanave, S. F. Bronk, N. W. Werneburg, and M. E. Fernandez-Zapico. 2010. Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB. J. Cell. Biochem. 110:1155-1164.
44. Moretta, A. 2002. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat. Rev. Immunol. 2:957-964.
45. Cooper, M. A., T. A. Fehniger, A. Fuchs, M. Colonna, and M. A. Caligiuri. 2004. NK cell and DC interactions. Trends Immunol. 25:47-52.
46. Degli-Esposti, M. A., and M. J. Smyth. 2005. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat. Rev. Immunol. 5:112-124.
47. Costantini, C., F. Calzetti, O. Perbellini, A. Micheletti, C. Scarponi, S. Lonardi, M. Pelletier, K. Schakel, G. Pizzolo, F. Facchetti, et al. 2011. Human neutrophils interact with both 6-sulfo LacNAc+ DC and NK cells to amplify NK-derived IFNgamma: role of CD18, ICAM-1, and ICAM-3. Blood 117:1677-1686.
48. Michel, T., F. Hentges, and J. Zimmer. 2012. Consequences of the crosstalk between monocytes/macrophages and natural killer cells. Front. Immunol. 3:403.
49. Hudspeth, K., E. Pontarini, P. Tentorio, M. Cimino, M. Donadon, G. Torzilli, E. Lugli, S. Della Bella, M. E. Gershwin, and D. Mavilio. 2013. The role of natural killer cells in autoimmune liver disease: a comprehensive review. J. Autoimmun. 46:55-65.
50. Pende, D., P. Rivera, S. Marcenaro, C. C. Chang, R. Biassoni, R. Conte, M. Kubin, D. Cosman, S. Ferrone, L. Moretta, and A. Moretta. 2002. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 62:6178-6186.
51. Varchetta, S., B. Oliviero, D. Mavilio, and M. U. Mondelli. 2013. Different combinations of cytokines and activating receptor stimuli are required for human natural killer cell functional diversity. Cytokine 62:58-63.
52. Johnson, K. W., B. H. Davis, and K. A. Smith. 1988. cAMP antagonizes interleukin 2-promoted T-cell cycle progression at a discrete point in early G1. Proc. Natl. Acad. Sci. USA 85:6072-6076.
53. Skålhegg, B. S., A. K. Johansen, F. O. Levy, K. B. Andersson, E. M. Aandahl, H. K. Blomhoff, V. Hansson, and K. Taskén. 1998. Isozymes of cyclic AMPdependent protein kinases (PKA) in human lymphoid cell lines: levels of endogenous cAMP influence levels of PKA subunits and growth in lymphoid cell lines. J. Cell. Physiol. 177:85-93.
54. Miller, J. S., T. Cervenka, J. Lund, I. J. Okazaki, and J. Moss. 1999. Purine metabolites suppress proliferation of human NK cells through a lineage-specific purine receptor. J. Immunol. 162:7376-7382.
55. Lieberman, L. A., and C. A. Hunter. 2002. Regulatory pathways involved in the infection-induced production of IFN-gamma by NK cells. Microbes Infect. 4:1531-1538.
56. Levy, E. M., M. P. Roberti, and J. Mordoh. 2011. Natural killer cells in human cancer: from biological functions to clinical applications. J. Biomed. Biotechnol. 2011:676198.
57. Kai, Z. S., and A. E. Pasquinelli. 2010. MicroRNA assassins: factors that regulate the disappearance of miRNAs. Nat. Struct. Mol. Biol. 17:5-10.
58. Volk, N., and N. Shomron. 2011. Versatility of MicroRNA biogenesis. PLoS ONE 6:e19391.
59. Ho, H. Y., H. H. Lee, and M. Z. Lai. 1997. Overexpression of mitogen-activated protein kinase kinase kinase reversed cAMP inhibition of NF-kappaB in T cells. Eur. J. Immunol. 27:222-226.
60. Gerlo, S., R. Kooijman, I. M. Beck, K. Kolmus, A. Spooren, and G. Haegeman. 2011. Cyclic AMP: a selective modulator of NF-κB action. Cell. Mol. Life Sci. 68:3823-3841.
61. Huang, Y. H., D. K. Sojka, and D. J. Fowell. 2012. Cutting edge: Regulatory T cells selectively attenuate, not terminate, T cell signaling by disrupting NF-κB nuclear accumulation in CD4 T cells. J. Immunol. 188:947-951.
62. Carr, L., A. Tucker, and R. Fernandez-Botran. 2003. In vivo administration of Ldopa or dopamine decreases the number of splenic IFN gamma-producing cells. J. Neuroimmunol. 137:87-93.
63. Cosentino, M., R. Bombelli, M. Ferrari, F. Marino, E. Rasini, G. J. Maestroni, A. Conti, M. Boveri, S. Lecchini, and G. Frigo. 2000. HPLC-ED measurement of endogenous catecholamines in human immune cells and hematopoietic cell lines. Life Sci. 68:283-295.
64. Deleidi, M., and T. Gasser. 2013. The role of inflammation in sporadic and familial Parkinson's disease. Cell. Mol. Life Sci. 70:4259-4273.
65. Chen, H., S. M. Zhang, M. A. Hernán, M. A. Schwarzschild, W. C. Willett, G. A. Colditz, F. E. Speizer, and A. Ascherio. 2003. Nonsteroidal antiinflammatory drugs and the risk of Parkinson disease. Arch. Neurol. 60:1059-1064.
66. Mihara, T., M. Nakashima, A. Kuroiwa, Y. Akitake, K. Ono, M. Hosokawa, T. Yamada, and M. Takahashi. 2008. Natural killer cells of Parkinson's disease patients are set up for activation: a possible role for innate immunity in the pathogenesis of this disease. Parkinsonism Relat. Disord. 14:46-51.
67. Mosley, R. L., J. A. Hutter-Saunders, D. K. Stone, and H. E. Gendelman. 2012. Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb. Perspect. Med. 2:a009381.
68. Solerte, S. B., L. Cravello, E. Ferrari, and M. Fioravanti. 2000. Overproduction of IFN-gamma and TNF-alpha from natural killer (NK) cells is associated with abnormal NK reactivity and cognitive derangement in Alzheimer's disease. Ann. N. Y. Acad. Sci. 917:331-340.
69. Blandini, F. 2013. Neural and immune mechanisms in the pathogenesis of Parkinson's disease. J. Neuroimmune Pharmacol. 8:189-201.
70. Ransohoff, R. M., P. Kivisäkk, and G. Kidd. 2003. Three or more routes for leukocyte migration into the central nervous system. Nat. Rev. Immunol. 3:569-581.
71. Poli, A., J. Kmiecik, O. Domingues, F. Hentges, M. Bléry, M. Chekenya, J. Boucraut, and J. Zimmer. 2013. NK cells in central nervous system disorders. J. Immunol. 190:5355-5362.
72. Segal, B. M. 2007. The role of natural killer cells in curbing neuroinflammation. J. Neuroimmunol. 191:2-7.